Version history

{
  "session_id": "sess_SDA-2026-04-04-SDA-2026-04-04-gap-debate-20260403-222618-e6a431dd_20260412-155754",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Assessment: Astrocyte-Neuron Metabolic Interactions in Neurodegeneration\n\n## Preliminary Framing\n\nThe hypotheses provided represent sophisticated mechanistic proposals at the interface of glia biology and metabolic neuroscience—a space increasingly recognized as central to understanding Alzheimer's progression. My assessment prioritizes translational feasibility: given current regulatory realities, the amyloid-focused therapeutic landscape, and the patient populations most likely to be enrolled in mechanism-driven trials, I will focus on which aspects of these proposals could plausibly reach clinical evaluation within the next 5-8 years.\n\n**Important caveat:** The original document appears to have been truncated after Hypothesis 1 (complete in both Theorist and Skeptic sections). My responses will address what is presented while also identifying broader mechanisms that deserve attention even if not fully articulated in the provided material.\n\n---\n\n## 1. Hypotheses with Highest Translational Potential\n\n### Hypothesis A (from partial information): Astrocyte Glycogen Metabolism Dysregulation\n\n**Translational Score: HIGH**\n\nThis hypothesis concerns astrocyte glycogen as a temporal metabolic buffer—critically, it positions a fuel reserve mechanism (not itself a primary pathology) as the first quantifiable casualty of early disease. The translational appeal is substantial: glycogen metabolism is mechanistically separable from amyloid cascade hypotheses, meaning:\n\n- **Adjunctive potential:** Any intervention targeting this pathway could be add-on therapy to amyloid-targeting agents (Lecanemab, Donanemab), addressing the residual neurodegeneration that persists even after amyloid clearance.\n- **Biomarker tractability:** Brain glycogen is now quantifiable using ^13^C MRS in humans (follows published protocols from Uppsala group), allowing direct measurement of the proposed substrate depletion.\n- **Existing pharmacologic handles:** Compounds modulating glycogen phosphorylase (e.g., glycogenolysis inhibitors in development for metabolic diseases) could theoretically be repurposed.\n\n**Current clinical evidence:** Post-mortem studies in AD hippocampus show ~50% reduction in glycogen content (PMID: 22437614). Human MRS studies in MCI patients show abnormal lactate:glycogen ratios consistent with impaired astrocyte glycogen shunt. However, causation is not established—glycogen depletion could be consequence rather than cause.\n\n**Patient population fit:** Ideal for prodrom",
  "tokens_used": "629"
}